These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 19549709)

  • 1. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
    Soria JC; Shepherd FA; Douillard JY; Wolf J; Giaccone G; Crino L; Cappuzzo F; Sharma S; Gross SH; Dimitrijevic S; Di Scala L; Gardner H; Nogova L; Papadimitrakopoulou V
    Ann Oncol; 2009 Oct; 20(10):1674-81. PubMed ID: 19549709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
    Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
    J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).
    White DA; Schwartz LH; Dimitrijevic S; Scala LD; Hayes W; Gross SH
    J Thorac Oncol; 2009 Nov; 4(11):1357-63. PubMed ID: 19745764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.
    Lara PN; Longmate J; Mack PC; Kelly K; Socinski MA; Salgia R; Gitlitz B; Li T; Koczywas M; Reckamp KL; Gandara DR
    Clin Cancer Res; 2015 Oct; 21(19):4321-6. PubMed ID: 26106072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
    Vansteenkiste J; Solomon B; Boyer M; Wolf J; Miller N; Di Scala L; Pylvaenaeinen I; Petrovic K; Dimitrijevic S; Anrys B; Laack E
    J Thorac Oncol; 2011 Dec; 6(12):2120-9. PubMed ID: 21900840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
    Gulley JL; Rajan A; Spigel DR; Iannotti N; Chandler J; Wong DJL; Leach J; Edenfield WJ; Wang D; Grote HJ; Heydebreck AV; Chin K; Cuillerot JM; Kelly K
    Lancet Oncol; 2017 May; 18(5):599-610. PubMed ID: 28373005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
    van den Eertwegh AJ; Karakiewicz P; Bavbek S; Rha SY; Bracarda S; Bahl A; Ou YC; Kim D; Panneerselvam A; Anak O; Grünwald V
    Urology; 2013 Jan; 81(1):143-9. PubMed ID: 23273080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribosomal S6 kinase and AKT phosphorylation as pharmacodynamic biomarkers in patients with myelodysplastic syndrome treated with RAD001.
    Advani AS; Mahfouz RZ; Maciejewski J; Rybicki L; Sekeres M; Tripp B; Kalaycio M; Bates J; Saunthararajah Y
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):172-177.e1. PubMed ID: 24332215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy--Chinese experiences.
    Ju Y; Hu Y; Sun S; Wang J; Jiao S
    Indian J Cancer; 2015 Nov; 52 Suppl 1():e32-6. PubMed ID: 26548937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.